Rapt Therapeutics, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
RAPT Therapeutics, Inc. has been acquired by GlaxoSmithKline LLC for $58.00 per share in cash, completing a tender offer and subsequent merger.
RAPT Therapeutics director Mary Ann Gray reports the disposition of common stock and stock options following the company's acquisition by GlaxoSmithKline LLC for $58.00 per share.
RAPT Therapeutics Director Michael F. Giordano reports the disposition of all common stock, RSUs, and stock options following the acquisition by GlaxoSmithKline LLC for $58.00 per share.
RAPT Therapeutics, Inc. director Ashley L. Dombkowski reports changes in beneficial ownership following the company's acquisition by GlaxoSmithKline LLC for $58.00 per share.
RAPT Therapeutics' Chief Financial Officer, Rodney Young, reported the disposition of common stock and conversion of stock options following the company's acquisition by GlaxoSmithKline for $58.00 per share.
RAPT Therapeutics Chief Scientific Officer Dirk G. Brockstedt disposed of common stock and stock options following the company's acquisition by GlaxoSmithKline LLC for $58.00 per share.
RAPT Therapeutics CEO Brian Russell Wong disposed of all common stock and stock options following the company's acquisition by GlaxoSmithKline for $58.00 per share.
RAPT Therapeutics Director Linda Kozick reports the disposition of common stock and stock options following the company's acquisition by GlaxoSmithKline at $58.00 per share.
RAPT Therapeutics Director Scott Braunstein reported the disposition of common stock and stock options following the company's acquisition by GlaxoSmithKline for $58.00 per share.
RAPT Therapeutics Director Scott Braunstein was granted 4,956 restricted stock units as part of the company's non-employee director compensation policy.
RAPT Therapeutics Director Michael F. Giordano was granted 4,956 restricted stock units as part of the company's non-employee director compensation policy.
RAPT Therapeutics Director Mary Ann Gray was granted 4,956 restricted stock units as part of her annual compensation, vesting in one year.
RAPT Therapeutics director Lori Lyons-Williams was granted 4,956 restricted stock units as part of the company's non-employee director compensation policy.
RAPT Therapeutics director Linda Kozick was granted 4,956 restricted stock units as part of the company's non-employee director compensation policy.
RAPT Therapeutics Director Ashley L. Dombkowski was granted 4,956 restricted stock units as part of the company's non-employee director compensation policy.
RAPT Therapeutics, Inc. Director Ashley L. Dombkowski was granted 25,000 stock options with an exercise price of $7.43, vesting over three years.
RAPT Therapeutics, Inc. Director Scott Braunstein was granted 25,000 stock options with an exercise price of $7.43, vesting over three years.
RAPT Therapeutics, Inc. Chief Medical Officer William Ho was granted 75,000 employee stock options with a vesting schedule commencing June 20, 2025.
RAPT Therapeutics, Inc. announced that its President and CEO, Brian Russell Wong, was granted 637,500 employee stock options with an exercise price of $7.43, vesting monthly over four years.
RAPT Therapeutics, Inc. Chief Financial Officer Rodney Young was granted 118,750 employee stock options with a vesting schedule commencing June 20, 2025.
Dirk G. Brockstedt, Chief Scientific Officer of RAPT Therapeutics, Inc., was granted 100,000 employee stock options with a vesting schedule over four years.
RAPT Therapeutics, Inc. has reported that Director Michael F. Giordano was granted 257,832 stock options with an exercise price of $0.93, vesting over 12 equal monthly installments.
RAPT Therapeutics, Inc. Director Mary Ann Gray was granted 257,832 stock options with an exercise price of $0.93, vesting over 12 months.
RAPT Therapeutics, Inc. Director Lori Lyons-Williams was granted 257,832 stock options with an exercise price of $0.93, vesting over 12 months.
RAPT Therapeutics, Inc. Director Linda Kozick was granted 257,832 stock options with an exercise price of $0.93, vesting over 12 months.
Director Wendye Robbins acquired stock options in RAPT Therapeutics in lieu of cash compensation for board service.
Form 4: RAPT Therapeutics Director, Mary Ann Gray, Acquires Stock Options in Lieu of Cash Compensation
Director Mary Ann Gray acquired stock options for 61,202 shares of RAPT Therapeutics at an exercise price of $1.22, vesting quarterly throughout 2025, in lieu of $65,000 in cash retainers.
RAPT Therapeutics, Inc. has granted its Chief Medical Officer, William Ho, an option to purchase 450,000 shares of common stock, according to a recent SEC filing.
RAPT Therapeutics' Chief Financial Officer, Rodney Young, acquired 642,000 employee stock options on January 30, 2025.
RAPT Therapeutics, Inc. has granted its Chief Scientific Officer, Dirk G. Brockstedt, options to purchase 515,000 shares of common stock, according to a recent SEC filing.